Cholesterol Biosynthesis is a Targetable Vulnerability of CEBPA -mutant Acute Myeloid Leukemia
Authors:
- Sofie Ulfbeck SchovsboSSSofie Ulfbeck Schovsbo
- Yang LiuYLYang Liu
- Pedro Aragon-FernandezPAPedro Aragon-Fernandez
- Sandra GordonSGSandra Gordon
- Mikkel Bruhn SchusterMSMikkel Bruhn Schuster
- Jinyu SuJSJinyu Su
- Sachin PundhirSPSachin Pundhir
- Nanna S MikkelsenNMNanna S Mikkelsen
- Erwin M SchoofESErwin M Schoof
- Kim Theilgaard-MönchKTKim Theilgaard-Mönch
- Kirsten GronbaekKGKirsten Gronbaek
- Rasmus O BakRasmus O Bak
Preprint
Abstract
Bi-allelic CEBPA mutations occur in 5-15% of acute myeloid leukemia (AML) patients. The precise molecular consequences of CEBPA mutations, especially in combination with frequently co-occurring mutations in TET2 , WT1 , and GATA2, remain incompletely understood. Here, we present a robust human model of CEBPA -mutant AML through gene editing of healthy bone marrow-derived hematopoietic stem cells. Loss of the CEBPA-p42 isoform expressed in healthy cells with concomitant upregulation of the leukemic CEBPA-p30 isoform resulted in a myeloproliferative phenotype. Concurrent loss-of-function mutations in TET2 or WT1 drove full leukemic transformation, while GATA2 haploinsufficiency promoted erythroid precursor accumulation without overt AML. Single-cell transcriptomics and low-input proteomics revealed enhanced myeloid output, increased interferon signaling and elevated cholesterol biosynthesis in leukemic cells. Targeting cholesterol synthesis enhanced chemosensitivity, highlighting a potential therapeutic vulnerability, particularly relevant for CEBPA -mutant patients harboring co-mutations in TET2 or WT1 , which have poor outcomes. Statement of significance: Induction of CEBPA-p30 by CRISPR/Cas gene editing in healthy human BM HSCs drives overt AML in vivo . TET2 and WT1 loss accelerate leukemogenesis, while GATA2 haploinsufficiency redirects differentiation toward erythroid precursors potentially driving acute erythroid leukemia. CEBPA-p30 AML exhibits cholesterol biosynthesis dependency, revealing a therapeutic vulnerability to statins.Keywords
Funding Information
- Rigshospitalets Forskningspulje
- Anders Hasselbalchs Fond
- Fabrikant Einar Willumsens Mindelegat
- The Lundbeck Foundation (R322-2019-2576)
- Danish Cancer Society (R340-A19670)
- Danish Cancer Society (R352-A20595)
- Danish Cancer Society (R223-A13071)
This publication has 71 references indexed in Scilit:
- Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imagingCell, 2024
- Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling PathwaysDrugs in R&D, 2023
- Integrated analysis of multimodal single-cell dataCell, 2021
- C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid ProgenitorCancer Cell, 2020
- Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityCell, 2019
- Prospective Isolation and Characterization of Genetically and Functionally Distinct AML SubclonesCancer Cell, 2018
- Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN SignalingCell, 2015
- DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid LeukemiaCell Reports, 2014
- Hematopoietic Stem Cell Expansion Precedes the Generation of Committed Myeloid Leukemia-Initiating Cells in C/EBPα Mutant AMLCancer Cell, 2009
- Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating CellsCancer Cell, 2008